Startup Funding Tracker
Home›People›James Healy
JH

James Healy

Director at BioAge Labs. Also a director at Seaport Therapeutics and Atsena Therapeutics.

DirectorPublic companyRoles at 3 startups
Updated Nov 9, 2026·Latest SEC filing Jun 12, 2026·Suggest an edit

About James Healy

James Healy is a director at BioAge Labs.

Form D filings also name James Healy as a director at Seaport Therapeutics and Atsena Therapeutics.

James Healy reports to the SEC as a director or major shareholder of 41 public companies, including Rapport Therapeutics (RAPP), Seaport Therapeutics (SPTX) and Y-mAbs Therapeutics (YMAB).

James Healy first appears on SEC filings in 2006.

Experience

This experience comes from SEC filings. The years are when the filings name James Healy in the role, so the role may have started earlier or lasted longer.

BioAge Labs, Inc.
Director
2024 – 2026 · Public company (BIOA)
Rapport Therapeutics, Inc.
Director
2024 – 2026 · Public company (RAPP)
Seaport Therapeutics, Inc.
Director
2024 – 2026 · Public company (SPTX)
Y-mAbs Therapeutics, Inc.
Director
2018 – 2025 · Public company (YMAB)
Natera, Inc.
Director
2015 – 2025 · Public company (NTRA)
Bolt Biotherapeutics, Inc.
Director
2021 – 2024 · Public company (BOLT)
Karuna Therapeutics, Inc.
Director
2019 – 2024 · Public company (KRTX)
ArriVent BioPharma, Inc.
Director
2024 · Public company (AVBP)
Atsena Therapeutics, Inc.
Director
2023 · Durham, NC
CinCor Pharma, Inc.
Director and 10% owner
2022 – 2023 · Public company (CINC)
Vera Therapeutics, Inc.
10% owner
2021 – 2023 · Public company (VERA)
Coherus Oncology, Inc.
Director
2014 – 2022 · Public company (CHRS)
Jade Biosciences, Inc.
10% owner
2021 · Public company (JBIO)
Checkmate Pharmaceuticals, Inc.
10% owner
2020 · Public company (CMPI)
Inozyme Pharma, Inc.
10% owner
2020 · Public company (INZY)
Akouos, Inc.
10% owner
2020 · Public company (AKUS)
Iterum Therapeutics plc
Director and 10% owner
2018 – 2020 · Public company (ITRM)
NextCure, Inc.
10% owner
2019 · Public company (NXTC)
Galera Therapeutics, Inc.
10% owner
2019 · Public company (GRTX)
Entasis Therapeutics Holdings Inc.
10% owner
2018 · Public company (ETTX)
Principia Biopharma Inc.
10% owner
2018 · Public company (PRNB)
PDS Biotechnology Corp
Director
2015 – 2017 · Public company (PDSB)
Marinus Pharmaceuticals, Inc.
10% owner
2014 – 2016 · Public company (MRNS)
Amarin Corp. PLC
Director and 10% owner
2010 – 2016 · Public company (AMRN)
Aclaris Therapeutics, Inc.
10% owner
2015 · Public company (ACRS)
Synlogic, Inc.
10% owner
2015 · Public company (SYBX)
aTYR PHARMA INC
10% owner
2015 · Public company (ATYR)
Hyperion Therapeutics Inc.
Director and 10% owner
2012 – 2015 · Public company (HPTX)
Spark Therapeutics, Inc.
10% owner
2015 · Public company (ONCE)
Ocugen, Inc.
10% owner
2014 · Public company (OCGN)
Intermune Inc.
Director
2006 – 2014 · Public company (ITMN)
Alimera Sciences Inc.
10% owner
2012 – 2014 · Public company (ALIM)
Aerie Pharmaceuticals Inc.
10% owner
2013 – 2014 · Public company (AERI)
Aravive, Inc.
10% owner
2014 · Public company (ARAV)
Ocera Therapeutics, Inc.
10% owner
2013 – 2014 · Public company (OCRX)
Anthera Pharmaceuticals Inc
Director and 10% owner
2010 – 2013 · Public company (ANTH)
Humanigen, Inc.
Director and 10% owner
2012 – 2013 · Public company (HGEN)
Durata Therapeutics, Inc.
Director and 10% owner
2012 · Public company (DRTX)
Trius Therapeutics Inc
10% owner
2010 – 2012 · Public company (TSRX)
Paratek Pharmaceuticals, Inc.
Director and 10% owner
2006 – 2008 · Public company (PRTK)
Anesiva, Inc.
10% owner
2007 · Public company (ANSV)
Cotherix Inc.
Director and 10% owner
2006 – 2007 · Public company (CTRX)

Key Colleagues at Startups

The people James Healy works with at each company, as listed on that company's latest Form D.

Seaport Therapeutics, Inc. · Form D, Oct 31, 2024
MC
Michael Chen
Executive officer
LG
Lana Gladstein
General Counsel
DZ
Daphne Zohar
Executive officer and director
AL
Antony Loebel
Executive officer
DW
EG
Eric Green
Executive officer
RN
SP
Steven Paul
Director
BC
DT
EE
Eric Elenko
Director
JP
Jason Pitts
Director
BioAge Labs, Inc. · Form D, Feb 13, 2024
EM
Eric Morgen
Director
DG
Dov Goldstein
Executive officer
JC
Jason Coloma
Director
KF
Kristen Fortney
CEO and director
PE
VP
Vijay Pande
Director
RH
Atsena Therapeutics, Inc. · Form D, Oct 2, 2023
MD
Michael Dial
Director
JW
JG
PR
Patrick Ritschel
Chief Executive Officer and director
SB
Shannon Boye
Director
EL
Elizabeth Leiderman
Executive officer
CI

Sources

  1. SECSeaport Therapeutics, Inc. Form D, filed Oct 31, 2024
  2. SECBioAge Labs, Inc. Form D, filed Feb 13, 2024
  3. SECAtsena Therapeutics, Inc. Form D, filed Oct 2, 2023
  4. SECForms 3, 4 and 5 filed by James Healy (SEC filer 1245624)